Mukherjee P et al., 2026: A paper combining a ketogenic diet with a benzimidazole in glioma used mebendazole (with devimistat), not fenbendazole, reporting benefit in juvenile mouse glioblastoma models and reduced proliferation of human SF-188 glioma cells.
The greatest reductions in tumor invasion and progression, together with prolonged survival, occurred when drug treatment was combined with a ketogenic diet (KD).
Mukherjee P et al., 2026: A paper combining a ketogenic diet with a benzimidazole in glioma used mebendazole (with devimistat), not fenbendazole, reporting benefit in juvenile mouse glioblastoma models and reduced proliferation of human SF-188 glioma cells. C3 glioblastoma + ketogenic diet. Study type: animal (VM-M3 and CT-2A syngeneic mouse glioblastoma) plus human pediatric glioma cell line SF-188; N not stated in abstract; country USA (Boston College, Seyfried lab); drugs mebendazole and devimistat (CPI-613), doses in full text; ketogenic diet as the metabolic vehicle; funder: not listed in the PubMed record; conflicts declared: B.G. formerly worked at BPG and S.A.S., J.J.A.-H., S.K., M.K. currently work at BPG (Bunge? as printed 'BPG'); maker N/A; comparators: drug alone vs drug plus ketogenic diet. FINDING: the book's 'glioblastoma with a ketogenic diet' research is a mebendazole study in mice; no fenbendazole-plus-ketogenic-diet study exists in PubMed (esearch 'ketogenic diet fenbendazole' returned 0). Study type: animal.
